Cardiac glycosides have played a prominent role in the therapy of congestive heart failure since William Withering codified their use in 1785.[1] In view of its narrow therapeutic index, limited published data on efficacy in children, and the widespread availability of newer drugs like angiotensin-converting enzyme (ACE) inhibitors and beta blockers, many clinicians have started questioning the role of digoxin in the present day management of heart failure in children. The gene discussed is ACE; the disease is heart failure.